Dallas, TX: ReportsandReports announce it will carry Bristol-Myers Squibb Co.: PharmaVitae Profile Market Research Report in its Store.
Browse complete Bristol-Myers Squibb Co.: PharmaVitae Profile Report
Introduction
This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Bristol-Myers Squibb’s performance against key rivals in the ethical pharmaceutical sector
- Assess how BMS is exploring the fast-growth oncology and immunology disease markets to drive long-term sales in the face of blockbuster patent expiry
- Investigate the strength of BMS’s pipeline, its product collaborations with AstraZeneca and Pfizer and the recent acquisition of Medarex.
Table of Content
ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Executive summary
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Sales data
Analyst consensus
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-15
Financial performance, 2003-15
Bristol-Myers Squibb: PharmaVitae forecasts at a glance
Strategic insight
Plavix dependency pushes BMS over 2012 patent cliff
BMS has the second fastest expiry decline within Big Pharma
BMS will focus on areas of high unmet need to mitigate the decline of its CV portfolio
BMS builds Big Pharma collaborations
Pfizer collaboration for apixaban
Antidiabetic collaboration with AstraZeneca
BMS fast evolving into a fully-fledged biopharmaceutical player
Productivity transformation initiative expected to lower operating costs by $2.5 billion by 2012
Increasingly profitable business model makes BMS an attractive M&A target
SWOT analysis
Table of Contents
Table of figures
Chapter 3 Quarterly news update
Latest quarterly sales
Latest comment
Q2 2010
ASCO 2010: ipilimumab achieves breakthrough in ‘long dark tunnel’ of metastatic melanoma
ASCO 2010: first-line chronic myeloid leukemia becomes next battleground for Sprycel and Tasigna
EASL 2010: promising developments in the hepatitis C pipeline
Q1 2010
Slow growth in cardiovascular disease will be offset by prospects in diabetes
Latest prescription pharma product news
Q3 2010
Q2 2010
Q1 2010
Latest corporate news
Q2 2010
Q1 2010
Future product milestones
Chapter 4 Company introduction
Key findings
Background
Key corporate developments
Bristol-Myers
Squibb
Bristol-Myers Squibb
M&A history
Medarex
Kosan Biosciences
Adnexus Therapeutics
Acordis Speciality Fibres
DuPont Pharmaceuticals
Mead Johnson
ConvaTec
Medical Imaging
Consumer Medicines
Oncology Therapeutics Network
Corporate restructuring to focus on pharma
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-15
Historical analysis
Forecast analysis
Product analysis
Product analysis, 2003-09
Product analysis, 2009-15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009-15
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09
Operating costs and profit analysis
Operating costs and profit analysis, 2003-09
Operating cost ratio and profit margin analysis, 2003-09
Operating cost ratio and profit margin analysis, 2009-15
Operating costs and profit analysis, 2009-15
Chapter 7 Key products
Overview
Plavix
Summary
Sales forecast
Reyataz
Summary
Sales forecast
Baraclude
Summary
Sales forecast
Orencia
Summary
Sales forecast
Sprycel
Summary
Sales forecast
Onglyza
Summary
Sales forecast
Erbitux
Summary
Sales forecast
Belatacept
Summary
Sales forecast
Sustiva
Summary
Sales forecast
Ipilimumab
Summary
Sales forecast
Abilify
Summary
Sales forecast
Ixempra
Summary
Sales forecast
Chapter 8 Appendix
References
Abbreviations
Exchange rates
About Datamonitor
About Datamonitor Healthcare
Datamonitor consulting
Disclaimer
Browse complete Bristol-Myers Squibb Co.: PharmaVitae Profile Report
Browse all Healthcare Market Research Reports
Browse all Datamonitor Market Research Reports RSS
Browse all Latest Report
Related Reports:
Bristol-Myers Squibb Co.-Deals & Alliances Report
Bristol-Myers Squibb Company-Detailed Product Pipeline
Bristol-Myers Squibb Company-Therapeutic Competitors
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
